Alcobra Ltd.

Industry · 8 registered clinical trials.

Status	Trial	Phase	Started
Terminated	The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD Attention Deficit Hyperactivity Disorder (ADHD)	Phase 3	2015-06-01
Completed	Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Ado ADHD, Predominantly Inattentive Type	Phase 2	2014-08-01
Completed	A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile Fragile X Syndrome	Phase 2	2014-06-01
Completed	A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity ) ADHD, Attention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type	Phase 2 / Phase 3	2014-03-01
Completed	A Phase 1 Study to Assess Pharmacokinetics of Metadoxine (MG01CI) 1400 mg, Administered to Healthy Volunteers Healthy Adult Subjects	Phase 1	2013-08-01
Completed	Study Comparing Two Doses of MG01CI and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyp ADHD Predominantly Inattentive Type	Phase 2	2013-08-01
Completed	Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorde ADHD	Phase 2	2011-02-01
Completed	Efficacy Study of Metadoxine SR Formulation in Attention Deficit Hyperactivity Disorder (ADHD) Subjects Attention Deficit Hyperactivity Disorder	Phase 1	2009-10-01